Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,901–10,000 of 15,747
Pallás, R. M. (2024) · Vacunas (English Edition) · doi:10.1016/j.vacune.2024.05.002 · Cited by 9
The role of media and community engagement in COVID-19 vaccinations in Tanzania
Kessy, A. T., Onuekwe, C. E., Mwengee, W., et al. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i3.705 · Cited by 4
“45 For example, a recent study in the US found that mixed or changing messages from health authorities during the pandemic exacerbated doubts and confusion, further eroding trust.”
Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy
Fay, M. P., Hunsberger, S., & Follmann, D. A. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3609 · Cited by 5
Ravindran, R., Szadkowski, L., Lovblom, L. E., Clarke, R., Huang, Q. W., Manase, D., Parente, L., & Walmsley, S. L. (2023) · PLOS Digital Health · doi:10.1371/journal.pdig.0000242 · Cited by 4
“Preventative vaccines were made available at exceptional speed and the initial protective rate of 90–94% for the 2-dose messenger RNA vaccines was far better than could have been anticipated [4,5].”
BackgroundChoi, M. J., Heo, J. Y., Seo, Y. B., Yoon, Y. K., Sohn, J. W., Noh, J. Y., Cheong, H. J., Kim, W. J., Choi, J., Lee, Y. J., et al. (2023) · Vaccines · doi:10.3390/vaccines11010120 · Cited by 4
“Both mRNA-1273 and BNT162b2 vaccines are the first human mRNA vaccines, which raised concerns about their immunological correlates with reactogenicity [3,30].”
BackgroundMarkovic, A., Kovačević, V., Brakenhoff, T. B., Veen, D., Klaver, P., Mitratza, M., Downward, G. S., Grobbee, D. E., Cronin, M., & Goodale, B. M. (2024) · Journal of Medical Internet Research · doi:10.2196/51120 · Cited by 3
Fisher, C. R., Medie, F. M., Luu, R. J., Quezada, L. A. L., Gaibler, R. B., Mulhern, T. J., Rubio, L. D., Marr, E. E., Gabriel, E. P., Borenstein, J. T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.07.495101 · Cited by 4
Bale, S., Gustchina, E., Guenaga, J., Ayala, V., Lee, W.-H., Ozorowski, G., Whitney, S., Wilson, R., Baboo, S., Diedrich, J. K., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01218-6 · Cited by 5
Safety and Considerations of the COVID-19 Vaccine Massive Deployment
Li, J., Song, M., Guo, D., & Yi, Y. (2021) · Virologica Sinica · doi:10.1007/s12250-021-00408-5 · Cited by 5
Taylor, K. N., DeLeo, R. A., Albright, E., Koebele, E. A., Birkland, T. A., Anderson, D., Zhang, M., & Shanahan, E. A. (2023) · European Policy Analysis · doi:10.1002/epa2.1198 · Cited by 5
Saito, M., Mori, A., Ishio, T., et al. (2024) · Viruses · doi:10.3390/v16030328 · Cited by 4
“Vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to be effective at suppressing the spread of this infection and preventing its severity [1,2].”
BackgroundShayak, B., Sharma, M., & Mishra, A. K. (2021) · medRxiv · doi:10.1101/2021.01.19.21250100 · Cited by 4
Zhao, Z., Salerno, S. M., Shi, X., Lee, S., Mukherjee, B., & Fritsche, L. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194341 · Cited by 4
“Results from early studies on the vaccines showed that serum IgG concentrations and SARS-CoV-2 neutralizing titers increased notably fourteen days after an individual’s second dose [30,31].”
BackgroundDemleitner, A. F., Wolff, A. W., Erber, J., Gebhardt, F. E., Westenberg, E., Winkler, A. S., Kolbe-Busch, S., Chaberny, I. F., & Lingor, P. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02484-7 · Cited by 5
Singh, B., & Rebennack, S. (2025) · IISE Transactions · doi:10.1080/24725854.2025.2525918 · Cited by 4
“Further, in the early stages of the COVID-19 pandemic, individuals with symptoms were prioritized for testing by the US Centers for Disease Control and Prevention (Ward et al., 2020).”
InfluentialHypermetabolic Axillary Lymphadenopathy on FDG PET/CT Due to COVID-19 Vaccination
Şahin, Ö. (2021) · Selçuk Tıp Dergisi · doi:10.30733/std.2021.01517 · Cited by 4
“Therefore, FDG PET/ CT studies constitute most cases in which vaccinerelated lymphadenopathies are presented in the literature, and higher incidences of HALN are reported with FDG PET/CT compared to clinical studies (5-14).”
BackgroundResultChanges in Blood Pressure After Pfizer/Biontech Sars-Cov-2 VaccinationPreprint
Ch’ng, C. C., Ong, L. M., & Wong, K. M. (2022) · Research Square · doi:10.21203/rs.3.rs-1018154/v1 · Cited by 4
Haque, S., Kumar, P., Mathkor, D. M., Bantun, F., Jalal, N. A., Mufti, A. H., Prakash, A., & Kumar, V. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2146752 · Cited by 4
Sanhueza, M., Barrera, M., Pedemonte, J. C., & Rojas, L. E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1164615 · Cited by 5
Influence of COVID ‐19 vaccination on disease activity of rheumatoid arthritis in older patients
Kobayashi, S., Kusuda, T., & Kubo, K. (2022) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14506 · Cited by 4
Emerging gene therapies for enhancing the hemostatic potential of platelets
Leung, J., Cau, M. F., & Kastrup, C. J. (2021) · Transfusion · doi:10.1111/trf.16519 · Cited by 5
Lee, J., Sachithanandham, J., Lee, J. S., Shapiro, J. R., Li, M., Sitaris, I., Peralta, S. R., Wouters, C., Cox, A. L., Segev, D. L., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02190-24 · Cited by 5
“S ARS-CoV-2 vaccines have remarkable efficacy and safety in both clinical trials and real-life practices (1–5).”
(2021) · doi:10.1101/2021.11.09.21266060 · Cited by 15
New-onset Seropositive Rheumatoid Arthritis Post-mRNA COVID-19 Vaccine: A Case Report
Almouslem, A., Lawati, T. A., Al-Shirawi, A., & Amri, U. A. (2023) · Oman Medical Journal · doi:10.5001/omj.2024.06 · Cited by 3
“Pfizer-BioNTech Vaccine is an example (2).”
Imaging Findings in Pediatric COVID-19: A Review of Current Literature
Fick, T. A., Cua, C. L., & Lee, S. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00256-8 · Cited by 4
“Specifically, changes in the spike protein in new variants have led to variations in vaccine protection [78].”
BackgroundRenteria-Flores, F. I., García‐Chagollán, M., & Jave‐Suárez, L. F. (2024) · Vaccines · doi:10.3390/vaccines12090968 · Cited by 7
“The current trend in vaccination is the use of lipid nanoparticles (LNPs) that encapsulate nucleic acids (e.g., BNT162b2 or mRNA-1273) [160,161].”
BackgroundSingle-dose SARS-CoV-2 vaccination efficacy in the elderly
Prendecki, M. F., & Willicombe, M. K. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00354-6 · Cited by 4
Enhanced mRNA delivery via incorporating hydrophobic amines into lipid nanoparticles
Wang, L., Li, Y., Jiang, P., Bai, H., Wu, C., Shuai, Q., & Yan, Y. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114528 · Cited by 5
Ito, S., Tsuchida, N., Kusunoki, S., Kaneko, Y., Naito, T., Hori, S., & Tobita, M. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126754 · Cited by 5
Stai, S., Λιούλιος, Γ., Christodoulou, M., Kasimatis, E., Fylaktou, A., & Stangou, M. J. (2022) · Life · doi:10.3390/life12091358 · Cited by 4
“stated that, since mRNA vaccines had prevented COVID-19 in a larger proportion of participants compared to ChAdOx nCoV-19 [15,45,46], they could possibly be a more suitable solution for immunocompromised individuals [43].”
BackgroundResultLee, K. Y., Song, K., Lee, K. H., Baek, J. Y., Kim, E. S., Song, Y. G., Kim, Y. C., Park, Y. S., Ahn, J. Y., Choi, J. Y., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.003 · Cited by 4
Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial
Phelps, C. C., Walker, C. M., & Honegger, J. R. (2021) · Viruses · doi:10.3390/v13071351 · Cited by 5
Gut microbiota: A potential player in psychiatric symptoms during COVID-19
Zeng, Z., & Tang, W. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2342846 · Cited by 4
Griessbach, A., Chammartin, F., Abela, I. A., Amico, P., Stoeckle, M. P., Eichenberger, A. L., Hasse, B. K., Braun, D. L., Schuurmans, M. M., Müller, T. F., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad536 · Cited by 5
“Approximately 1 year later, SARS-CoV-2 vaccines became available and were tested in large randomized placebo-controlled trials and determined safe and effective in terms of preventing COVID-19 [4, 5].”
BackgroundBonzano, L., Djurić, O., Mancuso, P., Fares, L., Brancaccio, R., Ottone, M., Bisaccia, E., Vicentini, M., Cocconcelli, A., Motolese, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10071111 · Cited by 4
Effect of booster vaccination against Delta and Omicron variants in Iceland
Norddahl, G., Melsted, P., Gunnarsdottir, K., Halldorsson, G., Olafsdottir, T., Gylfason, A., Kristjansson, M., Magnusson, O. T., Sulem, P., Gudbjartsson, D., et al. (2022) · medRxiv · doi:10.1101/2022.02.26.22271509 · Cited by 4
Buscot, M., Crémoni, M., Graça, D., Brglez, V., Courjon, J., Allouche, J., Teisseyre, M., Boyer, L., Barrière, J., Chamorey, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145652 · Cited by 5
Vacuna COVID-19 y pacientes anticoagulados por alto riesgo cardiovascular. Recomendaciones SEMERGEN
Pallarés‐Carratalá, V., García, J. P., Rioboó, E. M., et al. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2020.12.005 · Cited by 4
Vecchia, C. L., Centanni, S., & Gerli, A. G. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04286-5 · Cited by 4
Alexiev, I., Ivanov, I., Philipova, I. O., Korsun, N., Stoikov, I., Dimitrova, R., Grigorova, L., Gancheva, A., Trifonova, I. T., Dobrinov, V., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27394 · Cited by 5
“None of them were hospitalized; Case 1 with mild symptoms and Case 2 asymptomatic, which is in line with the known high effectiveness of the vaccine against severe COVID‐19 see Table 1.(7) Although the course of the infection was not life‐threatening, it raises questions related to asymptomatic carriers and the possib…”
BackgroundThe Use of Certainty in COVID-19 Reporting in Two Austrian Newspapers
Scherling, J., & Foltz, A. (2023) · Journalism and Media · doi:10.3390/journalmedia4020033 · Cited by 4
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S
Jacob-Dolan, C., Lifton, M. A., Powers, O. C., Miller, J. J., Hachmann, N. P., Vu, M. L., Surve, N., Mazurek, C. R., Fisher, J. L., Rodrigues, S. L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109716 · Cited by 7
Multiple evanescent white dot syndrome relapse following BNT162b2 mRNA COVID-19 vaccination
Séjournet, L., Rezkallah, A., Denis, P., et al. (2023) · International Journal of Ophthalmology · doi:10.18240/ijo.2023.10.25 · Cited by 4
Liontos, M., Kastritis, E., Markellos, C., Migkou, M., Eleftherakis-Papaiakovou, E., Koutsoukos, K., Gavriatopoulou, M., Zagouri, F., Ψαλτοπούλου, Θ., Terpos, E., et al. (2021) · Cancers · doi:10.3390/cancers13040763 · Cited by 4
van Balveren, L., van Puijenbroek, E., Davidson, L., & van Hunsel, F. P. A. M. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15678 · Cited by 5
Torres, M., Corona, M., Rodríguez-Mora, S., Casado‐Fernández, G., Zurdo-Castronuño, A., Mateos, E., Ramos-Martín, F., Sánchez-Menéndez, C., Murciano-Antón, M. A., García‐Pérez, J., et al. (2022) · Cancers · doi:10.3390/cancers14225537 · Cited by 5
“Even though protection against the Delta variant infection seems to decrease to 53.5–88% with two doses of COMIRNATY and 76–78% with two doses of Spikevax, prevention of severe infection and death remains adequate with 89–93.1% and 90–95%, respectively [16,60].”
InfluentialScoccianti, S., Paoli, C. D., Infantino, M. G., Paoletti, L., Caini, S., Meacci, F., Russo, S., Esposito, M., Fondelli, S., Leonulli, B. G., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110460 · Cited by 4
The Benefit of Cupping (Hijamah) to Post-Vaccination Mental & Physical Health
Zahrin, S. N. A., Said, M. M. M., Sandakumaran, A. I. M. I., et al. (2021) · Journal of KATHA · doi:10.22452/katha.vol17no1.2 · Cited by 4
Roman, I., Andreica, I., Baraliakos, X., Redeker, I., Kiltz, U., & Braun, J. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221093760 · Cited by 6
Leung, D., Cohen, C. A., Mu, X., Duque, J. S. R., Cheng, S. M. S., Wang, X., Wang, M., Zhang, W., Zhang, Y., Tam, I. Y. S., et al. (2022) · Frontiers in Immunology · doi:10.2139/ssrn.4115862 · Cited by 11
Mor, O., Zuckerman, N. S., Hazan, I., Fluss, R., Ash, N., Ginish, N., Mendelson, E., Alroy‐Preis, S., Freedman, L. S., & Huppert, A. (2021) · medRxiv · doi:10.1101/2021.07.20.21260833 · Cited by 8
da Silva, V. F., da Silveira, F. X., Borba, V. D. R., et al. (2022) · Reciis · doi:10.29397/reciis.v16i2.2373 · Cited by 4
Richter, D., & Theodoridou, A. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/8k7vt · Cited by 4
Do-Not-Resuscitate Orders by COVID-19 Status Throughout the First Year of the COVID-19 Pandemic
Piscitello, G. M., & Parker, W. F. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.09.024 · Cited by 4
Tang, Y., Lu, S., Liang, W., He, Y., Hao, J., Xu, W., Sun, Y., & Zhan, C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114465 · Cited by 10
Chen, S., Lan, J., Lu, Z., et al. (2025) · Vaccines · doi:10.3390/vaccines13090934 · Cited by 4
“The SARS-CoV-2 pandemic has accelerated the development of mRNA vaccines [5].”
Quiroga, B., Soler, M. J., Ortíz, A., & de Sequera, P. (2022) · Nefrología · doi:10.1016/j.nefro.2022.12.006 · Cited by 5
Grabowski, J., Niebrzydowska, A., Brzozowska, A., Waszak, P. M., Zagożdżon, P., Ali, S., Brancewicz, T., Wolff, M., Macul-Sanewska, A., & Bidzan, L. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10110320 · Cited by 5
“The most common AEFIs that were reported after the BNT162b2 vaccine included injection site pain, fatigue, muscle pain, local swelling, joint pain, headache, fever, chills, and nausea [12–17].”
Arregocés-Castillo, L., Fernández-Niño, J. A., Rojas-Botero, M. L., Palacios-Clavijo, A. F., Pedraza, M. G., Rincón, L. E., Pinto-Álvarez, M., Gómez, F. R., & Valdivia, B. T. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3978556 · Cited by 4
Wang, S., Zhang, Y., Ding, W., Meng, Y., Hu, H., Guan, Y., Zeng, X., Liu, Z., Meng, F., Wang, M., et al. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796025100243 · Cited by 8
“%) was reported in later sur-veysandthisstudy(Tan et al. , 2020), asthepandemicwasgradually controlled with vaccines(Fiolet et al. , 2022; Polack et al. , 2020).”
Kujur, M., Kiran, K. A., Nag, A. R., Soren, S. K., & Kujur, A. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_519_22 · Cited by 3
Improving mRNA vaccine safety and efficiency with cationized lipid nanoparticle formulaPreprint
Peng, X., Liao, G., Ren, D., Zhou, Y., Wu, X., Lei, Y., Zhang, Y., Chen, L., He, C., Zhang, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.29.534838 · Cited by 4
“Two Covid-19 mRNA vaccines (BNT162b2[1, 2] and mRNA-1273[3]), utilizing lipid nanoparticle (LNP) delivery technology, has been administered to billions of individuals worldwide, representing the first real-world application of prophylactic mRNA vaccines.”
BackgroundLepere, P., Escarguel, B., Yolartiran, S., & Escarguel, C. (2021) · medRxiv · doi:10.1101/2020.12.29.20248975 · Cited by 5
Janssen, C., Cachanado, M., Ninove, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3989843 · Cited by 4
Miyashita, N., Nakamori, Y., Ogata, M., Fukuda, N., Yamura, A., & Ishiura, Y. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.12.007 · Cited by 3
“16 SARS-CoV-2 vaccination [25-27] for the elderly was started in the 4 wave, and casirivimab-imdevimab [28] and sotrovimab [29] were available in the 5 wave.”
BackgroundB cell receptor repertoire analysis from autopsy samples of COVID-19 patients
Iwabuchi, S., Tsukahara, T., Okayama, T., Kitabatake, M., Motobayashi, H., Shichino, S., Imafuku, T., Yamaji, K., Miyamoto, K., Tamura, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1034978 · Cited by 5
“Randomized clinical trials of mRNAbased vaccines have reported up to 95% efficacies in the prevention of COVID-19 (1).”
BackgroundOuakka, A., Elazzouzi, A., & Hammouch, Z. (2023) · International Journal of Biomathematics · doi:10.1142/s1793524523500924 · Cited by 4
Jhanwar, A., Sharma, D., & Das, U. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134850 · Cited by 5
Kapoor, K. S., Harris, K., Arian, K. A., Ma, L., Church, K. A., & Kalluri, R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.12.561425 · Cited by 4
Confidence Intervals of COVID-19 Vaccine Efficacy Rates
Wang, F. (2021) · Numeracy · doi:10.5038/1936-4660.14.2.1390 · Cited by 4
Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection
(2021) · doi:10.1101/2021.07.09.21260266 · Cited by 4
“…use of S1 RBD for antibody testing has been extended to commercial assays and clinical applications (see list of emergency use authorized serology tests at fda. gov/medical-devices) since the introduction of SARS-CoV-2 vaccines, which contain S but not N (Jackson et al., 2020; Polack et al., 2020).”
Narita, D., Ebina‐Shibuya, R., Miyauchi, E., Tsukita, Y., Saito, R., Murakami, K., Kimura, N., & Sugiura, H. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.11.005 · Cited by 4
“[3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Suria, C., Boscá-Watts, M. M., Navarro, P., Tosca-Cuquerella, J., Antón, R., Sanahuja, A., Revaliente, M., & Mínguez, M. (2021) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2021.06.005 · Cited by 4
Kopčinović, L. M., Unić, A., Nikolac, N., Miler, M., Vrtarić, A., Božović, M., & Štefanović, M. (2023) · Laboratory Medicine · doi:10.1093/labmed/lmad044 · Cited by 4
Rikhi, N., Sei, C. J., Rao, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11091468 · Cited by 4
Lessons from the PROTECT-CH COVID-19 platform trial in care homes
Bath, P. M., Ball, J. K., Boyd, M., Gage, H., Glover, M. J., Godfrey, M., Guthrie, B., Hewitt, J., Howard, R. J., Jaki, T., et al. (2024) · Health Technology Assessment · doi:10.3310/mtrs8833 · Cited by 4
Shi, A., Tang, X., Xia, P., Hao, M., Shu, Y., Nakanishi, H., Smayra, K., Farzad, A., Hu, K., Liu, Q., et al. (2022) · medRxiv · doi:10.1101/2022.11.21.22282554 · Cited by 4
Self-citationRisk factors for long COVID among healthcare workers, Brazil, 2020–2022Preprint
Marra, A. R., Sampaio, V. D. S., Ozahata, M. C., Lopes, R., Brito, A. F., Bragatte, M. A. D. S., Kalil, J. E., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., et al. (2023) · medRxiv · doi:10.1101/2023.01.03.22284043 · Cited by 4
COVID-19 vaccine updates for people under different conditions
Huang, Y.-J., Wang, W., Liu, Y., Wang, Z., & Cao, B. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2643-1 · Cited by 6
“Furthermore, less frequent side effects have been observed for the Sinovac (inactivated vaccine) (Polack et al., 2020).”
InfluentialEvolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
Grandinetti, C. A., Budwal‐Jagait, M., Abid, H., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70120 · Cited by 4
A CRISPR response to pandemics?
Germani, F., Wäscher, S., & Biller‐Andorno, N. (2021) · EMBO Reports · doi:10.15252/embr.202052319 · Cited by 4
Chou, E. H.-C., Wang, C., Tsai, C., Garrett, J. S., Bhakta, T., Shedd, A., Hassani, D. M., Risch, R., d’Etienne, J. P., Ogola, G., et al. (2021) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2021.5.52583 · Cited by 5
Siegrist, C., & Eberhardt, C. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00002-5 · Cited by 6
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Henriquez, S., Zerbit, J., Bruel, T., Ouedrani, A., Planas, D., Deschamps, P., Staropoli, I., Hadjadj, J., Varet, B., Suarez, F., et al. (2021) · medRxiv · doi:10.1101/2021.08.08.21261769 · Cited by 4
Hashan, M. R., Smoll, N. R., Chapman, G., King, C. L., Walker, J., Kirk, M., Akbar, D., Booy, R., & Khandaker, G. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-073555 · Cited by 6
Holtkamp, C., Schöler, L., Anastasiou, O. E., Brune, B., Fessmann, K., Elsner, C., Möhlendick, B., Čiučiulkaitė, I., Dudda, M., Trilling, M., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12746 · Cited by 4
COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
Krantz, M. S., & Phillips, E. J. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00123-2 · Cited by 6
Khowaja, S. A., Khuwaja, P., & Dev, K. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2101.02030 · Cited by 14
Booster vaccination against SARS-CoV-2: current challenges and solutions
Drapkina, O. M., Berns, S. A., Gorshkov, A. Y., Иванова, А. А., Ryzhakova, L. N., & Bashnyak, V. S. (2022) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2022-11-2-196-203 · Cited by 5
Chambers, C. Z., Soo, G. L., Engel, A. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.13.548758 · Cited by 4
Kim, H. R., Kim, S., Chang, M. S., Lee, C. S., Byeon, S. H., Kim, S. S., Lee, S. W., & Kim, Y. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.01.038 · Cited by 7
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.